SEC Form 4 · accession 0001171000-15-000106
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Heffernan
Officer — Chief Executive Officer
Period of report
Nov 23, 2015
Accepted (ET)
Nov 24, 2015 · 3:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Nov 23, 2015 | M | 7,250 | $0.125 | A | 19,334 | D | |
| Ordinary SharesF1 | holding | — | — | — | 243,587 | I | By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase SharesF1,F2 | $0.125 | Nov 23, 2015 | M | 7,250 | D | — | Nov 5, 2020 | Ordinary Shares | 7,250 | 9,666 | I |
Explanation of responses
- F1The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- F27,250 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 4,833 options to purchase shares will vest and become exercisable on each of 7/1/16 and 7/1/17.